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Myostatin, a negative regulator of skeletal muscle growth, is produced
from myostatin precursor by multiple steps of proteolytic processing. After
cleavage by a furin-type protease, the propeptide and growth factor
domains remain associated, forming a noncovalent complex, the latent
myostatin complex. Mature myostatin is liberated from latent myostatin by
bone morphogenetic protein 1/tolloid proteases. Here, we show that, in
reporter assays, latent myostatin preparations have significant myostatin
activity, as the noncovalent complex dissociates at an appreciable rate, and
both mature and semilatent myostatin (a complex in which the dimeric
growth factor domain interacts with only one molecule of myostatin pro-
peptide) bind to myostatin receptor. The interaction of myostatin receptor
with semilatent myostatin is efficiently blocked by WAP, Kazal, immuno-
globulin, Kunitz and NTR domain-containing protein 1 or growth and dif-
ferentiation factor-associated serum protein 2 (WFIKKN1), a large
extracellular multidomain protein that binds both mature myostatin and
myostatin propeptide [Kondas et al. (2008) J Biol Chem 283, 23677–23684].
Interestingly, the paralogous protein WAP, Kazal, immunoglobulin, Kunitz
and NTR domain-containing protein 2 or growth and differentiation
factor-associated serum protein 1 (WFIKKN2) was less efficient than
WFIKKN1 as an antagonist of the interactions of myostatin receptor with
semilatent myostatin. Our studies have shown that this difference is attrib-
utable to the fact that only WFIKKN1 has affinity for the propeptide
domain, and this interaction increases its potency in suppressing the recep-
tor-binding activity of semilatent myostatin. As the interaction of
WFIKKN1 with various forms of myostatin permits tighter control of
myostatin activity until myostatin is liberated from latent myostatin by
bone morphogenetic protein 1/tolloid proteases, WFIKKN1 may have
greater potential as an antimyostatic agent than WFIKKN2.
Structured digital abstract
 Furin cleaves Promyostatin by protease assay (View interaction)
 myostatin binds to PRO by surface plasmon resonance (View interaction)
 BMP-1 cleaves Promyostatin by protease assay (View interaction)
Abbreviations
ACRIIB, activin receptor IIB receptor tyrosine kinase, the high-affinity type II receptor of myostatin; BMP, bone morphogenetic protein;
ECD_ACRIIB, extracellular domain of activin receptor IIB receptor tyrosine kinase; GDF8, growth and differentiation factor 8 or myostatin;
PRO116–266, C-terminal region of the myostatin prodomain; PRO43–115, N-terminal region of the myostatin prodomain; SPR, surface plasmon
resonance; TGF, transforming growth factor; WFIKKN1, WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 or
growth and differentiation factor-associated serum protein 2; WFIKKN2, WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing
protein 2 or growth and differentiation factor-associated serum protein 1.
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 ACR IIB physically interacts with Latent Myostatin by surface plasmon resonance (View interaction)
 Promyostatin and Promyostatin bind by comigration in gel electrophoresis (View interaction)
 WFIKKN1 binds to Latent Myostatin by pull down (View interaction)
 ACR IIB binds to Mature Myostatin by surface plasmon resonance (View Interaction: 1, 2, 3)
 WFIKKN1 binds to Myostatin Prodomain by surface plasmon resonance (View Interaction: 1, 2, 3)
Introduction
Myostatin, a member of the transforming growth fac-
tor (TGF)-b family, is a negative regulator of skeletal
muscle growth: mice lacking myostatin or carrying
mutations in the gene for myostatin precursor are
characterized by a dramatic increase in skeletal muscle
mass [1,2]. Mutations in the myostatin gene were also
shown to cause the double-muscling phenotype in cat-
tle [3–6].
These findings have raised the possibility that myost-
atin could be an important therapeutic target for mus-
cle wasting-related disorders, and that antimyostatic
agents might be used to treat myopathic diseases in
which increasing muscle mass is desirable [7].
Several studies have confirmed that blocking myost-
atin signaling has beneficial effects in models of muscle
degenerative diseases such as the mdx mouse model of
Duchenne muscular dystrophy. Blockade of endoge-
nous myostatin with blocking antibodies resulted in a
significant increase in body weight, muscle mass, mus-
cle size, and absolute muscle strength [8]. Wagner
et al. showed that, when myostatin null mutant mice
were crossed with mdx mice, the mice lacking myosta-
tin were stronger and more muscular than their mdx
counterparts [9].
Recent studies have shown that antagonists of myo-
statin may also be useful in preventing muscle wasting
and loss of muscle force associated with cancer and in
the alleviation of sarcopenia, the reduction in muscle
mass and strength that is often observed with aging
[10,11].
The myostatin-inhibitory activity of myostatin
prodomain has been exploited in several studies to
increase muscle mass in neonatal and adult mice
[12,13], to enhance muscle regeneration following
injury [14], and to ameliorate the dystrophic phenotype
in mdx mice [15,16].
Myostatin is similar to other members of the TGF-b
family in that it is synthesized as a large precursor
protein; two molecules of myostatin precursor are
covalently linked via a single disulfide bond present in
the C-terminal growth factor domain (Fig. 1).
The mature growth factor, myostatin/growth and
differentiation factor 8 (GDF8), is liberated from
myostatin precursor through multiple steps of
proteolytic processing (Fig. 1). In the first step of the
myostatin activation pathway, a unique peptide bond,
the Arg266-Asp267 bond, is cleaved by proprotein
convertases in both chains of the homodimeric precur-
sor, but the two propeptide domains and the disulfide-
bonded, homodimer consisting of growth factor
domains remain associated, forming a noncovalent
complex [17]. As the binding of myostatin to its
Fig. 1. Schematic representation of the domain structure of human
prepromyostatin. The vertical dashed lines indicate the positions of
the sites of cleavage by furin-type proteases and BMP-1, and S
indicates the signal peptide. The bottom part of the figure
illustrates the position of the various prodomain fragments used in
the present work. The numbers refer to the residue numbering of
human prepromyostatin.
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cognate receptor, AC RIIB, can be inhibited with high
concentrations of myostatin propeptide, it was con-
cluded that the noncovalent propeptide–myostatin
complex is inactive, justifying the term latent myosta-
tin for this complex [17,18].
The observation that, in blood, myostatin circulates
in the form of noncovalent complexes that are com-
pletely inactive provided further support for the view
that the propeptide–myostatin complex is inactive; in
reporter assays, the myostatin activity of serum
became significant only after acid treatment [19].
The implicit conclusion from these studies (that the
propeptide–myostatin complex is completely inactive),
however, is not fully justified, as myostatin propeptide
is not the only protein that forms a noncovalent com-
plex with myostatin in serum. It seems to be clear that
the ‘latency’ of serum myostatin is also attributable to
the presence of proteins that are more potent inhibi-
tors of myostatin activity than the propeptide. In fact,
Lee and McPherron were the first to show that follist-
atin is a much more potent inhibitor of myostatin than
the propeptide [17].
Moreover, Hill et al. [20,21] have shown that
circulating myostatin is bound to at least two other
inhibitory binding proteins with high affinity, the
FSTL3/FLRG protein (the product of the follistatin-
related gene, FLRG) and another follistatin-related
protein, WAP, Kazal, immunoglobulin, Kunitz and
NTR domain-containing protein 2 or growth and dif-
ferentiation factor-associated serum protein 1
(WFIKKN2)/GASP1 (the product of the WFIKKN2
gene). As the affinity of mature myostatin is signifi-
cantly higher for WFIKKN2 than for myostatin pro-
peptide [22], it seems to be clear that lack of activity
of serum myostatin preparations cannot be attributed
solely to the myostatin–propeptide interaction.
It should be emphasized that, although for some
TGF-b family members (e.g. TGF-b1, TGF-b2, and
TGF-b3), prodomains bind with high enough affinity
to completely suppress biological activity, the activity
of many other TGF-b ligands is not blocked by the
presence of the prodomain [23]. For example, Sengle
et al. [24,25] have shown that complex formation
between the prodomain and growth factor domains of
bone morphogenetic proteins BMP-4, BMP-5 and
BMP-7 does not inhibit their activity, whereas the
prodomain of BMP-10 is similar to those of TGF-b1,
TGF-b2 and TGF-b3 in that it is a potent inhibitor of
BMP-10 activity.
Although the molecular basis of these differences
has not been fully explored, it should be noted that,
in the crystal structure of latent TGF-b1, the prodo-
main shields the growth factor from recognition by
type I and type II receptors [26]. In the TGF-b1–
prodomain complex, the dimeric growth factor
domain is enclosed in a ‘straightjacket’ formed by the
two prodomains, and in this case the stability of the
‘straitjacket’ is reinforced by two reciprocal interchain
disulfide bonds between Cys223 and Cys225 of the
prodomain of TGF-b1 [26]. As the sequences of all
33 TGF-b family members indicate a similar prodo-
main fold [26], it seems safe to assume that, in each
case, complex formation between the prodomain and
the growth factor domain blocks the access of recep-
tors to the growth factors. In this case, the most
plausible explanation for the observation that some
prodomain complexes are ‘inactive’ (e.g. TGF-b1,
TGF-b2, TGF-b3, and BMP-10), whereas others are
‘active’ (e.g. BMP-4, BMP-5, and BMP-7), is that the
active complexes dissociate at a much higher rate
than the inactive complexes. Consistent with this
assumption, inspection of the data of Sengle et al.
(Fig. 2B of [25]) indicates that the ‘active’ BMP-4
and BMP-5 complexes dissociate at a significantly
higher rate than the ‘inactive’ BMP-10–prodomain
complex.
Accordingly, we assume that, in the TGF-b family,
the activity of prodomain–growth factor complexes
varies on a continuous scale, from zero activity in the
case of tight complexes (such as those of TGF-b1,
TGF-b2, and TGF-b3) to nearly full activity in the
case of rapidly dissociating complexes. Several studies
suggest that – on this scale of activity – the myosta-
tin–prodomain complex occupies an intermediate posi-
tion: the complex may not be tight enough to render it
completely inactive. For example, inspection of the
data of Wolfmann et al. (Fig. 2B in [27]) indicates
that, in reporter assays, the latent myostatin complex
shows significantly higher myostatin activity than con-
trol samples.
Whether or not the myostatin–propeptide complex
can be equated with a completely inactive latent com-
plex, mature growth factor can be liberated from this
complex through degradation of the propeptide: mem-
bers of the BMP-1/tolloid family of metalloproteinases
cleave a single peptide bond of the propeptide of myo-
statin (the Arg98-Asp99 bond), with concomitant
release of the growth factor [27].
The importance of BMP-1-mediated cleavage of
myostatin propeptide for the liberation of mature
myostatin is underlined by the fact that mice carrying
a point mutation that rendered the propeptide BMP-1-
resistant showed increases in muscle mass [28]. The
increases in muscle mass, however, were significantly
lower than those seen in mice completely lacking myo-
statin, suggesting that cleavage at this site is not an
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absolute requirement for of myostatin activity [28]. A
possible explanation for the residual myostatin activity
of mice carrying BMP-1-resistant myostatin is that the
latent myostatin complex is not completely inactive.
One of the goals of our present study was to investi-
gate the molecular basis of the activity of latent myost-
atin preparations.
As pointed out above, the activity of mature myost-
atin liberated from myostatin precursor is controlled
by several proteins, other than the prodomain; these
include follistatin [17], FLST3/FLRG [20], WFIKKN1
and WFIKKN2 proteins [21,22].
WFIKKN1 and WFIKKN2 are two closely related
multidomain proteins that contain a WAP domain, a
follistatin/Kazal domain, an immunoglobulin domain,
two Kunitz domains, and an NTR domain [29,30].
WFIKKN1 and WFIKKN2 are unique among
myostatin-binding proteins in that they have higher
specificity for myostatin (and the closely related
growth and differentiation factor 11 or BMP-11) than
follistatin or FLST3/FLRG [21,22,31], making them
attractive as agents of antimyostatic therapy. Recent
studies showed that adeno-associated virus-mediated
delivery of WFIKKN2 into the muscles of wild-type
mice resulted in an approximately 30% increase in
muscle mass of the treated animals [32]. Similarly,
transgenic mice overexpressing WFIKKN2 were found
to have larger muscles than wild-type animals [33].
Another feature of WFIKKN1 that may also
enhance its myostatin specificity is that, in addition to
its interaction with mature myostatin, it was shown to
display affinity for myostatin propeptide [22]. Our
structure–function studies on WFIKKN1 have
revealed that its follistatin domain is primarily respon-
sible for the binding of mature myostatin, whereas its
NTR domain contributes most significantly to the
interaction with myostatin propeptide [22].
Although nothing is known about the biological sig-
nificance of the interaction of myostatin propeptide
with WFIKKN1, in view of the fact that WFIKKN
proteins are potent antagonists of myostatin, we have
suggested that the interaction of WFIKKN1 with the
propeptide domain may also serve to interfere with the
release of mature growth factor from the precursor
and/or the latent complex of myostatin [34].
The goal of our present work was to investigate this
hypothesis.
Our studies have shown that latent myostatin has
significant myostatin activity, as the noncovalent com-
plex dissociates at an appreciable rate, and both
mature and semilatent myostatin (the complex in
which the dimeric growth factor domain interacts with
only one molecule of myostatin propeptide) bind to
myostatin receptor. The interactions of myostatin
receptor with semilatent myostatin are efficiently
blocked by WFIKKN1, but the paralogous protein
WFIKKN2 is less efficient than WFIKKN1, as only
WFIKKN1 has affinity for the propeptide domain.
Our data suggest that WFIKKN1 may ensure tighter
control of myostatin activity until myostatin is liber-
ated from latent myostatin by BMP-1/tolloid prote-
ases, and that WFIKKN1 may therefore have greater
potential as an antimyostatic agent than WFIKKN2.
Results and Discussion
Latent myostatin preparations have significant
activity
As discussed above, according to the generally
accepted view, latent myostatin is completely inactive;
it does not trigger the signal transduction cascade, as
it is unable to bind to the myostatin receptor. Accord-
ing to this view, active mature myostatin may be liber-
ated from the latent complexes only through
degradation of the prodomain by members of the
BMP-1/tolloid family of metalloproteinases or by
denaturation of the prodomain.
It was therefore somewhat unexpected that, in our
reporter assays, latent myostatin had significant activ-
ity even in the absence of BMP-1 cleavage or heat
treatment (Fig. 2): in these assays, the latent myostatin
complex always showed significantly (P < 0.05) higher
myostatin activity than control samples. Comparison
of the dose–response curves of latent myostatin prepa-
rations and heat-treated latent myostatin preparations
confirmed that latent myostatin preparations had low
but significant activity (Fig. 2B).
In view of the activity of latent myostatin in repor-
ter assays, it was of major interest to decide whether
this activity was an inherent property of the latent
complex or whether mature myostatin was liberated
from the complex during the reporter assay.
In principle, there are several (not mutually exclu-
sive) explanations for the activity of latent myostatin
preparations in reporter assays: (a) the myostatin–
prodomain complex has detectable activity, as its
growth factor domain interacts with the cognate recep-
tor; (b) the myostatin–prodomain complex dissociates
at a significant rate during the assay, and the release
of both prodomains makes the dimeric growth factor
accessible to its cognate receptor; (c) the myostatin–
prodomain complex dissociates at a significant rate
during the assay, and the release of one prodomain
makes the growth factor domain in this complex
(semilatent complex) partially accessible to its cognate
FEBS Journal 280 (2013) 3822–3839 ª 2013 The Authors. FEBS Journal published by John Wiley & Sons Ltd on behalf of FEBS 3825
Gy€orgy Szlama et al. WFIKKN1 inhibits the activity of latent myostatin
receptor; and (d) during the assay, latent myostatin is
activated by some protease present in the reporter
assay system.
In favor of alternatives (b) and (c), one might argue
that, because the KD of the interaction of myostatin
with its prodomain is in the ~ 108 M range [17,22,25],
in this concentration range latent myostatin prepara-
tions may contain a significant proportion of mature
myostatin and semilatent myostatin, and these species
may account for the activity observed in various
assays.
To answer these questions, we first monitored the
interaction of promyostatin, latent myostatin prepara-
tions and mature myostatin with the high-affinity
type II receptor of myostatin, activin receptor IIB
(ACRIIB) [17,35], using surface plasmon resonance
(SPR)-based real-time in vitro assays, where alternative
(d) can be ruled out. Our SPR analyses showed that
promyostatin did not bind to the extracellular domain
of the receptor (ECD_ACRIIB) (Fig. 3A), consistent
with the observation that promyostatin is inactive in
reporter assays (see column B in Fig. 2); however,
latent myostatin (either the complex or some constitu-
ents in equilibrium with the complex) was found to
bind to ECD_ACRIIB (Fig. 3B).
The strongest argument against the view that this
binding activity is an inherent property of the myosta-
tin–propeptide complex [alternative (a)] came from
SPR experiments in which we preincubated constant
concentrations of myostatin with increasing concentra-
tions of myostatin prodomain, and injected these sam-
ples onto extracellular domain of ACRIIB
(ECD_ACRIIB) chips (Fig. 4). Analysis of the sensor-
grams indicated that, at high prodomain concentra-
tions, where the molar ratio of prodomain and
myostatin dimer was > 1, the SPR signal was com-
pletely blocked; that is, saturation of myostatin with
the prodomain completely prevents its binding to the
receptor. Half-maximal inhibition was achieved with
~ 1 9 108 M myostatin prodomain.
The fact that promyostatin does not interact with
the receptor (Fig. 3A) also argues against the notion
that the myostatin growth factor domain might inter-
act with the receptor even when it is associated with
the prodomains.
Our finding that the observed rate of association of
latent myostatin with immobilized ECD_ACRIIB was
not a linear function of the concentration of latent
myostatin (see insert in Fig. 3B) also argues against
alternative (a). The most plausible explanation of this
deviation from linearity is that the increase in latent
complex concentration does not result in a propor-
tional increase in activity, because, at high concentra-
tions, a smaller proportion of the protein exists
as the dissociated species, and the latter may be
responsible for the observed activity [alternatives (b)
and (c)].
Comparison of SPR sensorgrams of the interaction
of the receptor with latent myostatin and with mature
myostatin (Fig. 3B,C) suggests that alternative (b)
(that is, free mature myostatin present in latent
myostatin preparations might be responsible for the
activity) cannot fully account for the activity of
the latent myostatin preparations: the kinetics of the
A B
Fig. 2. Luciferase reporter assay of myostatin activity of promyostatin and its derivatives. (A) Rhabdomyosarcoma A204 cells were
transiently transfected with the SMAD Luciferase Reporter vector and a Renilla luciferase vector, and incubated for 16 h with different
forms of myostatin. Firefly luciferase units were normalized to Renilla luciferase units. A, control medium; B, 5 nM promyostatin; C, 5 nM
latent myostatin; D, 5 nM BMP-1-digested latent complex; E, 5 nM latent myostatin incubated at 80 °C for 5 min. (B) A204 cells transiently
transfected with the SMAD Luciferase Reporter vector and a Renilla luciferase vector were incubated for 6 h with different concentrations
of latent complex (▲) or with different concentrations of latent complex incubated at 80 °C for 5 min (●). Firefly luciferase units were
normalized to Renilla luciferase units. Note that latent myostatin had significant activity even in the absence of BMP1-cleavage or heat
treatment. Values are means  standard errors. *P < 0.05 versus control samples; **P < 0.01 versus control samples.
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interaction of latent myostatin differ significantly from
those observed in the case of mature myostatin. In the
case of latent myostatin, the dissociation rate constant
was significantly (P < 0.01) higher than in the case of
mature myostatin; for the myostatin–ACRIIB interac-
tion, the kd is (3.59 9 10
4)  (2.73 9 105) s1,
whereas for the latent complex, this value is
(2.27 9 103)  (2.8 9 104) s1. It should also be
noted that not only did heat treatment of latent myo-
statin result in a marked increase in SPR response, but
that the complex dissociated with a dissociation rate
constant of (6.1 9 104)  (1.69 9 105) s1; figure
not shown), similar to that observed in the case of the
myostatin–ECD_ACRIIB interaction.
These observations suggest that alternative (c) con-
tributes to the observed activity of latent myostatin
preparations. Direct evidence for the ability of semila-
tent myostatin to bind to myostatin receptor came
from experiments in which we first injected myostatin
onto the surface of the ECD_ACRIIB chip, and then
injected increasing concentrations of myostatin prodo-
main. The fact that, in this experimental set-up, injec-
Fig. 4. Myostatin prodomain blocks the interaction of mature myostatin with ECD_ACRIIB. SPR sensorgrams of the interactions of
immobilized ECD_ACRIIB with 10 nM myostatin preincubated with 0, 1, 2, 5, 10, 20, 50 and 100 nM myostatin prodomain are shown.
Various concentrations of myostatin prodomain and 10 nM myostatin were preincubated in 20 mM Hepes, 150 mM NaCl, 5 mM EDTA and
0.005% Tween-20 (pH 7.5) for 30 min at room temperature, and were injected over CM5 sensorchips containing immobilized ECD_ACRIIB.
For the sake of clarity, the concentrations of myostatin prodomain injected over the sensorchip are not indicated in the panels; the SPR
response decreased in parallel with the increase in myostatin prodomain concentration. The insert shows that the value of the apparent
association rate kobs decreased with the increase in myostatin prodomain concentration. Note that 50 nM myostatin prodomain completely
eliminated the interaction; half-maximal inhibition was achieved with ~ 1 9 108 M myostatin prodomain. RU - SPR Response Units.
A B C
Fig. 3. Comparison of the interactions of promyostatin, latent myostatin and mature myostatin with ECD_ACRIIB. Promyostatin (100, 500,
and 1000 nM) (A), latent myostatin (25, 100, 200, 350, 500, and 1000 nM (B) or mature myostatin (10, 20, 35, 50, 100, and 200 nM (C) in
20 mM Hepes, 150 mM NaCl, 5 mM EDTA and 0.005% Tween-20 (pH 7.5) were injected over the surface of CM5 sensorchips containing the
ligand-binding extracellular domain of ACRIIB. The insert in (B) shows the apparent association rate constants kobs as a function of latent
myostatin concentration. The observation that the value of kobs did not increase linearly with the increase in analyte concentration indicates
that the proportion of receptor-binding species decreased with the increase in total latent myostatin concentration. RU - SPR Response Units.
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tion of the prodomain led to a significant further
increase in SPR response (Fig. 5A) (although no
increase was observed when only the prodomain was
injected onto ECD_ACRIIB chips) indicates that biva-
lency of the myostatin dimer permits its simultaneous
association with a molecule of the receptor and one
molecule of the prodomain. It is noteworthy that the
KD of the interaction of the prodomain with the myo-
statin–ECD_ACRIIB complex is 3.0 9 108 M
(Fig.5B), similar to that determined for the prodo-
main–myostatin interaction [17,22,25].
These findings indicate that the myostatin dimer
complexed with one molecule of the prodomain (i.e.
semilatent myostatin) can bind to the myostatin recep-
tor, suggesting that semilatent myostatin can trigger
the signal transduction cascade. We suggest that the
activity of semilatent myostatin may provide an expla-
nation for the activity of latent myostatin preparations
and the residual myostatin activity of BMP-1-resistant
latent myostatins [28].
Promyostatin binds WFIKKN1 but not WFIKKN2
In view of our observation that semilatent myostatin
has significant myostatin activity, it was of major
interest to determine whether WFIKKN proteins can
interfere with the activity of this complex.
In our earlier work, we have shown that the
multidomain protein WFIKKN1 has affinity for two
distinct regions of myostatin precursor: mature myost-
atin and the prodomain of myostatin [22]. We have
also shown that mature myostatin binds to the follista-
tin-related domain of WFIKKN1, whereas binding of
the prodomain of myostatin is mediated by the NTR
domain of WFIKKN1. Studies by Hill et al. [21] sug-
gested that WFIKKN2 might be similar to WFIKKN1
in that WFIKKN2 also appeared to have affinity for
both mature myostatin and myostatin prodomain.
In order to explore the possibility that WFIKKN1
and WFIKKN2 might also interact with the prodo-
main and/or growth factor domain of intact promyost-
atin, we immobilized recombinant human WFIKKN1
and WFIKKN2 on the surface of CM5 sensorchips,
and performed SPR measurements with recombinant
promyostatin.
These experiments showed (Fig. 6A,B) that prom-
yostatin has affinity for WFIKKN1 (KD of 1 9
106 M) but not for WFIKKN2. As, in promyostatin,
the growth factor domain is inaccessible to the recep-
tor (Fig. 3A), the most plausible explanation for this
observation is that WFIKKN1 binds promyostatin
through its interaction with the prodomain region.
A weak point of this explanation, however, is that
earlier data of Hill et al. [21] suggested that
WFIKKN2 also has affinity for myostatin prodomain:
if WFIKKN1 and WFIKKN2 are similar in that both
proteins have affinity for myostatin prodomain, and if
WFIKKN1 binds promyostatin through the prodo-
A B
Fig. 5. Myostatin prodomain binds to the myostatin–myostatin receptor complex. (A) The myostatin–ECD_ACRIIB complex was formed by
injection of 100 nM myostatin over the surface of immobilized ECD_ACRIIB, and, after the completion of the injection, different
concentrations of myostatin prodomain (0, 20, 50, 100, 200, and 500 nM) were injected over the receptor–myostatin complex. For the sake
of clarity, the concentrations of prodomain injected over the sensorchip are not indicated in the panels; the SPR response increased with
the increase in myostatin prodomain concentration. (B) Sensorgrams of the interaction of myostatin prodomain with the ACRIIB–myostatin
complex fitted with the 1 : 1 interaction model of BIAEVALUATION 4.1. The sensorgrams in (B) were calculated from those shown in (A) by
subtracting the RU values observed at 0 nM myostatin prodomain. The equilibrium dissociation constant of the interaction of myostatin
prodomain with the myostatin–ECD_ACRIIB complex was 3 9 108 M. RU - SPR Response Units.
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main, then WFIKKN2 would also be expected to bind
promyostatin.
To resolve this contradiction, we performed experi-
ments to characterize the interaction of WFIKKN1 and
WFIKKN2 with myostatin prodomain in greater detail,
in quantitative terms, using SPR technology. (Note that
the earlier conclusion of Hill et al. that WFIKKN2
binds the prodomain of myostatin was based on
qualitative observations in pull-down experiments.)
Myostatin prodomain has affinity for WFIKKN1
but not for WFIKKN2
Our studies on the interaction of recombinant myosta-
tin prodomain with immobilized WFIKKN1 and
WFIKKN2 revealed that myostatin prodomain inter-
acted with WFIKKN1; the KD for the binding of myo-
statin prodomain to WFIKKN1 was calculated to be
2 9 108 M (Fig. 7A).
Myostatin prodomain, however, did not bind to
WFIKKN2 (Fig. 7B). As this finding contradicts the
earlier conclusion of Hill et al. [21], it was important to
exclude the possibility that our failure to demonstrate
an interaction between myostatin prodomain and
WFIKKN2 reflects some difference in the sensitivities
of WFIKKN1 and WFIKKN2 to immobilization.
To exclude this possibility, we also performed solution-
competition assays. In these assays, we preincubated
myostatin prodomain withWFIKKN1 orWFIKKN2 to
monitor the effect of soluble WFIKKNs on the
WFIKKN1–prodomain interaction. These experiments
showed that even thehighest concentration (1 lM)of solu-
bleWFIKKN2wasunable to interferewith the bindingof
myostatin prodomain (200 nM) to immobilized
WFIKKN1 (Fig. 7D), whereas WFIKKN1 efficiently
inhibited the interaction (Fig. 7C).
WFIKKN1 binds the C-terminal subdomain of
myostatin prodomain
Earlier studies on myostatin prodomain have shown
that its N-terminal region (encompassing residues
42–115 of myostatin precursor) plays a critical role in
the interaction of the prodomain with mature myosta-
tin, whereas the C-terminal region (residues 99–266)
does not exhibit inhibitory activity [36]. Jiang et al.
[36] suggested that the C-terminal region may play a
role in the stability of myostatin propeptide, and that
the inhibitory subdomain is located in the region
between residues 42 and 115.
It should be noted that this division of myostatin
prodomain into two distinct subdomains is in agree-
ment with the known structure of the TGF-b1 precur-
sor [26]. The N-terminal region of myostatin
prodomain (which inhibits myostatin activity)
corresponds to the straitjacket part of the TGF-b1
precursor that encircles and forms intimate con-
tacts with each growth factor monomer, whereas the
A B
Fig. 6. Interaction of promyostatin with immobilized WFIKKN1 and WFIKKN2. (A) Sensorgrams of the interactions of promyostatin (50, 100,
250, 500, 1000, 1500, 2000, and 2500 nM) with WFIKKN1. (B) Sensorgrams of the interactions of promyostatin (100, 500, and 2000 nM)
with WFIKKN2. Various concentrations of promyostatin in 20 mM Hepes, 150 mM NaCl, 5 mM EDTA and 0.005% Tween-20 (pH 7.5) were
injected over CM5 sensorchips containing immobilized WFIKKN1 or WFIKKN2. For the sake of clarity, the concentrations of promyostatin
are not indicated in the panels; in (A), the SPR response increased in parallel with the increase of promyostatin concentration. In (A), the
inset shows the equilibrium responses plotted against the concentration of injected promyostatin; the equilibrium dissociation constant was
determined by fitting the curve with the general fitting model ‘Steady state affinity’ of BIAEVALUATION 4.1. The equilibrium dissociation
constant of the interaction of promyostatin with WFIKKN1 was ~ 1 9 106 M. RU - SPR Response Units.
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C-terminal region aligns with the region of the TGF-
b1 precursor that folds into a unique fold that is criti-
cal for prodomain dimerization.
In order to define the region within myostatin prodo-
main that is necessary for the binding of the prodomain
to WFIKKN1, we produced two prodomain fragments
(Fig. 1): the N-terminal region corresponding to the
myostatin-binding region (PRO43–115), and the C-termi-
nal region of myostatin prodomain (PRO116–266). In
agreement with the conclusion of Jiang et al. [36], our
SPR experiments confirmed that only the N-terminal
region of the prodomain binds mature myostatin
A B
C D
Fig. 7. Interaction of myostatin prodomain with immobilized WFIKKN1 and WFIKKN2. (A) Sensorgrams of the interactions of myostatin
prodomain (25, 50, 100, 200, 350, 500, 750, and 1000 nM) with WFIKKN1. (B) Sensorgrams of the interactions of myostatin prodomain
(100, 500, and 1000 nM) with WFIKKN2. Various concentrations of myostatin prodomain in 20 mM Hepes, 150 mM NaCl, 5 mM EDTA and
0.005% Tween-20 (pH 7.5) were injected over CM5 sensorchips containing immobilized WFIKKN1 or WFIKKN2. For the sake of clarity, the
concentrations of myostatin prodomain are not indicated in these panels; in (A), the SPR response increased in parallel with the increase in
myostatin prodomain concentration. The response curves were fitted with the 1 : 1 interaction model of BIAEVALUATION 4.1, and the KD for
binding of WFIKKN1 to myostatin prodomain was calculated to be 2 9 108 M (A). Note that WFIKKN2 did not bind myostatin prodomain
(B). (C) Sensorgrams of the interaction of immobilized WFIKKN1 with 200 nM myostatin prodomain preincubated with or without 1 lM
WFIKKN1. (D) Sensorgrams of the interaction of immobilized WFIKKN1 with 200 nM myostatin prodomain preincubated with or without
1 lM WFIKKN2. Mixtures of WFIKKN1 or WFIKKN2 with myostatin prodomain were incubated for 30 min in 20 mM Hepes, 150 mM NaCl,
5 mM EDTA and 0.005% Tween-20 (pH 7.5) before injection over CM5 sensorchips containing immobilized WFIKKN1. Note that soluble
WFIKKN1 efficiently inhibited the interaction of myostatin prodomain with immobilized WFIKKN1 (C), whereas soluble WFIKKN2 had no
effect on the interaction (D). RU - SPR Response Units.
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(Fig. 8A,B): the KD of the interaction was calculated to
be 3.7 9 106 M.
Conversely, when we studied the interaction of the two
prodomain fragments with WFIKKN1, no interaction
was detected in the case of PRO43–115 (Fig. 8C), whereas
PRO116–266 had affinity for immobilized WFIKKN1; the
KD for the binding of PRO116–266 to WFIKKN1 was
calculated to be 4.3 9 107 M (Fig. 8D).
In summary, myostatin prodomain appears to
consist of two functionally distinct subdomains: the N-
terminal subdomain binds mature myostatin, whereas
the C-terminal subdomain binds WFIKKN1.
Latent myostatin binds WFIKKN1 but not
WFIKKN2
In view of our observation that WFIKKN1 and
WFIKKN2 are markedly different in that only
WFIKKN1 has significant affinity for myostatin
prodomain (and promyostatin), we examined whether
this difference also holds for their affinity for latent
myostatin.
To answer this question, we performed Ni2+–
Sepharose based pull-down experiments. In these
experiments, latent myostatin was incubated with
A B
C D
Fig. 8. Myostatin and WFIKKN1 bind to different regions of myostatin prodomain. (A) Sensorgrams of the interaction of PRO43–115 (500 nM,
1 lM, 2 lM, 5 lM, and 10 lM) with immobilized myostatin. (B) Sensorgram of the interaction of PRO116–266 (1 lM) with immobilized
myostatin. Note that myostatin bound to the N-terminal region but not the C-terminal region of myostatin prodomain. (C) Sensorgrams of
the interaction of PRO43–115 (400 nM, 1 lM, and 2.5 lM) with immobilized WFIKKN1. (D) Sensorgrams of the interaction of PRO116–266
(50 nM, 100 nM, 200 nM, 500 nM, 1 lM, and 5 lM) with immobilized WFIKKN1. Note that WFIKKN1 bound to the C-terminal region but not
the N-terminal region of myostatin prodomain. Various concentrations of prodomain fragments in 20 mM Hepes, 150 mM NaCl, 5 mM EDTA
and 0.005% Tween-20 (pH 7.5) were injected over the surface containing immobilized myostatin (A, B) or immobilized WFIKKN1 (C, D). The
inset in (D) shows the equilibrium response plotted against the concentration of injected PRO116–266. The equilibrium dissociation constant
was determined by fitting the curve with the general fitting model ‘Steady state affinity’ of BIAEVALUATION 4.1, and the KD for binding of
WFIKKN1 to PRO116–266 was calculated to be 4.3 9 10
7
M. RU - SPR Response Units.
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WFIKKN1 or WFIKKN2 (both containing C-termi-
nal His-tags) or with buffer alone, and the equilib-
rium mixtures were applied to an Ni2+-affinity
matrix. Unbound proteins were washed out, and the
bound proteins were eluted as described in Experi-
mental procedures. The eluted samples were analyzed
by SDS/PAGE, and the proteins were visualized by
staining with Coomassie Brilliant Blue and by wes-
tern blotting with specific antibodies against myosta-
tin prodomain (anti-prodomain) and against mature
myostatin (anti-myostatin). Our analyses showed
(Fig. 9) that both constituents of the latent complex
(myostatin prodomain and mature myostatin) were
pulled down by WFIKKN1, but neither of them was
pulled down by WFIKKN2. The pull-down experi-
ments thus confirm that there is a marked difference
between WFIKKN1 and WFIKKN2 in that the for-
mer forms a relatively tight complex with latent myo-
statin, but no similar complex exists in the case of
WFIKKN2.
WFIKKN1 blocks the receptor-binding activity of
latent myostatin preparations more effectively
than WFIKKN2
In order to explore whether the interaction of
WFIKKN1 with latent myostatin affects the ability of
the latter to give rise to molecular species (myostatin
and semilatent myostatin) that can activate its cognate
receptor, we compared the influence of WFIKKN1
and WFIKKN2 on the interactions of the latent myo-
statin preparations with ECD_ACRIIB chips.
Latent myostatin preparations (500 nM) were preincu-
bated with increasing concentrations of WFIKKN1 or
WFIKKN2, the mixtures were injected onto ECD_
ACRIIB chips, and the SPR responses were recorded.
As shown in Fig. 10, both WFIKKN1 and WFIKKN2
inhibited the interaction but WFIKKN1 was more
effective; half-maximal inhibition of the interaction was
achieved with 1 9 109 M and 5 9 109 M WFIKKN1
and WFIKKN2, respectively.
It noteworthy that, in these experiments, half-maxi-
mal inhibition of the receptor-binding activity of
500 nM latent myostatin was achieved with nanomolar
concentrations of both WFIKKNs, making it clear
that the active species (myostatin and/or semilatent
myostatin) constitute a small fraction of the latent
myostatin preparation. The fact that, despite the huge
excess of prodomain–myostatin complex, WFIKKN1
is able to block the activity of semilatent myostatin
suggests that WFIKKN1 has significantly higher affin-
ity for semilatent myostatin than for the latent myosta-
tin complex. The most plausible explanation for this
difference is that, in the latent complex (as in prom-
yostatin), only the prodomain is accessible for interac-
tion with the NTR domain of WFIKKN1, whereas in
the case of the semilatent complex, the partially
exposed growth factor domain can also interact with
the follistatin domain of WFIKKN1, substantially
increasing the overall affinity of the two proteins.
In the case of WFIKKN2, the affinity for semilatent
myostatin is defined only by its interaction with the
partially exposed growth factor domain, explaining
why it is a less efficient inhibitor of the activity of
semilatent myostatin.
It should be noted that this difference between the
potencies of WFIKKN1 and WFIKKN2 in inhibiting
the activity of semilatent myostatin is just the opposite
of what one would expect on the basis of their ability
to bind and inhibit mature myostatin. We have shown
Fig. 9. Latent myostatin binds WFIKKN1 but not WFIKKN2. In
Ni2+-affinity pull-down assays, 1 lM latent myostatin was
incubated for 1 h with 2 lM His-tagged WFIKKN1 or 2 lM His-
tagged WFIKKN2 in NaCl/Pi containing 50 mM imidazole, 0.1%
Tween-20 and 100 lM phenylmethanesulfonyl fluoride (pH 7.5),
and the solutions were then mixed with 20 lL of Ni2+–
nitrilotriacetic acid resin. After 15 min of agitation, the resin was
washed with NaCl/Pi, 50 mM imidazole, 0.5% Tween-20 and
100 lM phenylmethanesulfonyl fluoride (pH 7.5), and the bound
proteins were eluted with NaCl/Pi and 500 mM imidazole (pH 7.5).
The eluted samples were analyzed by SDS/PAGE, and the
proteins were visualized by staining with Coomassie Brilliant Blue
and by western blotting with specific antibodies against myostatin
prodomain (anti-prodomain) and against mature myostatin (anti-
myostatin). LM, latent myostatin. The numbers indicate the
molecular mass values of proteins of the Low Molecular Weight
Calibration Kit. In the upper panel, the proteins were visualized by
staining with Coomassie Brilliant Blue; in the lower panels, the
proteins were visualized by western blotting.
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previously [22] that WFIKKN2 has significantly higher
affinity for mature myostatin than WFIKKN1:
whereas the KD of the myostatin–WFIKKN1 interac-
tion is 3.35 9 108 M, this value for the myostatin–
WFIKKN2 interaction is 2.86 9 1010 M.
In summary, we assume that the increased potency
of WFIKKN1 as an inhibitor of the activity of latent
myostatin preparations is explained by the fact that
it interacts with two different domains of semilatent
myostatin: the prodomain and the growth factor
domain. As WFIKKN2 has practically no affinity
for the prodomain, its ability to inhibit the activity
of latent myostatin preparations may be mediated
only by its interaction with the growth factor
domain.
It should be noted that the various promyostatin
derivatives used in the present work were recombi-
nant proteins produced in Escherichia coli; therefore,
they lack the glycosylations that might occur in mam-
mals. Accordingly, we must not ignore the possibility
that the lack of glycosylation might have affected
some of the protein–protein interactions that we
investigated. Human prepromyostatin has only one
N-glycosylation site, at position 71; this site is located
in the N-terminal subdomain of the prodomain,
which plays a critical role in its interaction with
mature myostatin.
In view of the fact that the C-terminal subdomain
of myostatin prodomain (which lacks glycosylation
sites) interacts with WFIKKN1 but not with
WFIKKN2, it seems unlikely that the difference
between the affinities of the two WFIKKN proteins
for various promyostatin derivatives is attributable to
the lack of glycosylation at residue 71.
Conclusion
We have shown that latent myostatin preparations
have significant myostatin activity, because, in these
preparations, the inactive, noncovalent latent myosta-
tin complex is in equilibrium with significant concen-
trations of mature myostatin and semilatent myostatin
(a prodomain–myostatin complex in which the dimeric
growth factor domain interacts with only one molecule
of myostatin prodomain), both of which may bind to
the myostatin receptor.
The activity of latent myostatin preparations is
blocked by both WFIKKN1 and WFIKKN2, but
WFIKKN1 was found to be a more potent inhibitor
than WFIKKN2. As this observation is in sharp con-
trast to the fact that WFIKKN2 has significantly
higher affinity for mature myostatin than WFIKKN1
[22], it is clear that the increased potency of
A
B
C
Fig. 10. WFIKKN1 and WFIKKN2 inhibit the binding of latent
myostatin to ECD_ACRIIB. (A) Sensorgrams of the interactions of
immobilized ECD_ACRIIB with 500 nM latent myostatin
preincubated with WFIKKN1 (0, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25,
and 50 nM). (B) Sensorgrams of the interactions of immobilized
ECD_ACRIIB with 500 nM latent myostatin preincubated with
WFIKKN2 (0, 0.25, 0.5, 1, 2.5, 5, 10, 25, 50, and 100 nM). For the
sake of clarity, the concentrations of WFIKKNs are not indicated in
the panels; the SPR response decreased in parallel with the
increase in WFIKKN concentration. (C) Values of the apparent
association constant kobs from (A) and (B) were plotted against
WFIKKN1 (▼) and WFIKKN2 (●) concentrations. Note that kobs
values decreased with the increase in WFIKKN1 or WFIKKN2
concentration; half-maximal inhibition was achieved with
~ 1 9 109 M WFIKKN1 or ~ 5 9 109 M WFIKKN2. In these
experiments, various concentrations of WFIKKN1 or WFIKKN2
were preincubated with latent myostatin in 20 mM Hepes, 150 mM
NaCl, 5 mM EDTA and 0.005% Tween-20 (pH 7.5) for 30 min at
room temperature, and were injected over CM5 sensorchips
containing immobilized ECD_ACRIIB. RU - SPR Response Units.
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WFIKKN1 reflects its influence on the activity of
semilatent myostatin rather than on mature myostatin.
Our studies suggest that the increased potency of
WFIKKN1 as an inhibitor of the activity of semilatent
myostatin is attributable to the fact that WFIKKN1
interacts not only with the growth factor domain but
also with the prodomain constituent of the latent myo-
statin complex. Structure–function studies on the inter-
action of WFIKKN1 with myostatin prodomain
revealed that this interaction is mediated by the C-ter-
minal subdomain of myostatin prodomain. In contrast
to WFIKKN1, WFIKKN2 has practically no affinity
for myostatin prodomain, explaining why it is a less
efficient inhibitor of latent myostatin preparations.
Our finding that the interaction of WFIKKN1 with
various forms of myostatin permits tighter control of
myostatin activity until myostatin is liberated from
latent myostatin by BMP-1/tolloid proteases suggests
that WFIKKN1 may have greater potential as an anti-
myostatic agent than WFIKKN2.
Experimental procedures
Reagents, enzymes, PCR primers, proteins,
bacterial strains, cell lines, and media
Restriction enzymes and T4 DNA ligase were from New
England Biolabs (Beverly, MA, USA). PCR primers were
from Integrated DNA Technologies (Coralville, IA, USA).
For amplification reactions, we used the proofreading ther-
mostable polymerase Accuzyme (Bioline, London, UK).
DNA purification was performed with the Nucleospin
Extract PCR purification kit (Macherey-Nagel, Duren,
Germany). E. coli JM109 was used for DNA propagation
during DNA manipulation steps, and E. coli BL21(DE3)
strain was used for protein expression. CM5 sensorchips
and the reagents for protein coupling to the chips were
from Biacore AB (Uppsala, Sweden). Recombinant human
WFIKKN1, human WFIKKN2 and the extracellular
region of ACRIIB were produced as described previously
[22,31]. Myostatin antibody (AF788) and myostatin pro-
peptide antibody (AF1539) for western blots were from
R&D Systems (Wiesbaden, Germany). Alkaline phospha-
tase-conjugated secondary antibodies (A4187 and A5187)
and Whatman Protran BA-83 nitrocellulose membrane
were from Sigma Aldrich (St. Louis, MO, USA). Nitro
Blue tetrazolium and 5-bromo-4-chloroindol-2-yl phosphate
were from Serva Electrophoresis (Heidelberg, Germany).
The Cignal SMAD Reporter Kit was from SaBioscienc-
es/Qiagen (Frederick, MD, USA), and the firefly and Renil-
la luciferase kits were from Biotium (Hayward, CA, USA).
Rhabdomyosarcoma A204 cells were from the German
Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany). Culture medium (McCoy’s 5A)
and heat-inactivated fetal bovine serum were from Invitro-
gen (Carlsbad, CA, USA). Fugene HD transfection
reagent was from Promega Corporation (Madison, WI,
USA).
Reporter assay
Rhabdomyosarcoma A204 cells were cultured in
McCoy’s 5A supplemented with 10% fetal bovine serum,
penicillin (100 UmL1) and streptomycin (100 lgmL1) at
37 °C in a 5% CO2 atmosphere.
For reporter assays, 3 9 104 cells were plated in wells of
a 96-well plate and allowed to attach for 24 h. The cells
were transiently transfected with 100 ng of Cignal SMAD
Luciferase Reporter vector mixture and 0.3 lL of Fugene
HD reagent per well, according to the manufacturer’s
instructions. Transfections were performed in serum-free
McCoy’s 5A containing 1 mgmL1 BSA without antibiot-
ics. Eighteen hours later, the transfection medium was
changed to McCoy’s 5A containing 1 mgmL1 BSA, and
conditioned for 6 h. McCoy’s 5A containing 1 mgmL1
BSA and 5 nM recombinant proteins was added to the cells
and, after 18 h, the cells were washed with NaCl/Pi and
lysed with 50 lL of passive lysis buffer (Promega Corpora-
tion). Firefly and Renilla luciferase activities were measured
on an Enspire Multimode Reader (PerkinElmer, Waltham,
MA, USA). The firefly luciferase units obtained were nor-
malized to the Renilla luciferase units to generate relative
luciferase units. In all cases, six parallel experiments were
performed and were repeated three times.
Protein analyses
The composition of protein samples was analysed by SDS/
PAGE under both reducing and nonreducing conditions.
The gels were stained with Coomassie Brilliant Blue G-250.
The concentrations of the recombinant proteins were
determined with the following extinction coefficients: prom-
yostatin, 55 640 M1cm1; myostatin prodomain, 35 200
M
1cm1; PRO43–115, 8480 M1cm1; PRO116–266, 21
095 M1cm1; WFIKKN1, 64 440 M1cm1; WFIKKN2,
57 470 M1cm1; and ECD_AVRIIB, 26 065 M1cm1.
The extinction coefficients were calculated with the online
protein analysis tool PROTPARAM.
N-terminal sequencing of the purified recombinant
proteins was performed on an Applied Biosystems 471A
protein sequencer with an online ABI 120A phenylthiohyd-
antoin analyzer (Applied Biosystems, Foster City, CA,
USA).
SPR measurements
SPR measurements were performed on a BIACORE X
(GE Healthcare, Stockholm, Sweden) instrument. During
immobilization, 5 lL of 0.5 lM WFIKKN1 and
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WFIKKN2 solutions in 50 mM sodium acetate (pH 4.5)
buffer, and 50 lL of 10 lM ECD_ACRIIB solution in
sodium acetate buffer (pH 3.5), were injected, with a
5 lLmin1 flow rate, onto a CM5 sensor chip activated by
the amine coupling method according to the instructions of
the manufacturer.
For interaction measurements, 80-lL aliquots of different
concentrations of analyte solutions were injected over the sen-
sor chips with a flow rate of 20 lLmin1. Binding and
washes were performed in 50 mM Hepes, 150 mM NaCl,
1 mM EDTA, and 0.01% Tween-20 (pH 7.5). After each
cycle, the chips were regenerated by injection of 40 lL of 8 M
urea, 50 mM Hepes, 150 mM NaCl, 1 mM EDTA, and 0.01%
Tween-20 (pH 7.5).
Control flow cells were prepared by performing the cou-
pling reaction in the presence of coupling buffer alone.
Control flow cells were used to obtain control sensorgrams
showing nonspecific binding to the surface as well as
refractive index changes resulting from changes in bulk
properties of the solution. Control sensorgrams were sub-
tracted from sensorgrams obtained with immobilized
ligand. To correct for differences between the reaction and
reference surfaces, we also subtracted the average of sen-
sorgrams obtained with blank running buffer injections.
Unless otherwise indicated, the kinetic parameters of the
interactions were determined by globally fitting the experi-
mental data with the 1 : 1 interaction model of BIAEVALUA-
TION 4.1. In the case of interactions that reached
equilibrium by the end of the injection phase, we plotted
the responses at equilibrium against the analyte concentra-
tions, and fitted the curve with the general fitting model
‘Steady state affinity’ of BIAEVALUATION 4.1.
Analysis of protein–protein interactions by
pull-down assays
Protein pairs were incubated together for 1 h in NaCl/Pi,
50 mM imidazole, 0.1% Tween-20 and 100 lM phen-
ylmethanesulfonyl fluoride (pH 7.5) at 4 °C, and the solu-
tions were then mixed with 20 lL of Ni2+–nitrilotriacetic
acid resin (GE Healthcare, Little Chalfont, UK) and
loaded on a Pierce spin column (Thermo Scientific, Wal-
tham, MA, USA).
The sealed columns were incubated for 15 min with con-
stant agitation at room temperature. The columns were
washed twice with 200 lL of NaCl/Pi, 50 mM imidazole,
0.5% Tween-20, and 100 lM phenylmethanesulfonyl fluo-
ride (pH 7.5), and once with 200 lL of NaCl/Pi, 50 mM
imidazole, 0.1% Tween-20, and 100 lM phen-
ylmethanesulfonyl fluoride (pH 7.5). The bound proteins
were eluted with NaCl/Pi and 500 mM imidazole (pH 7.5).
The composition of the eluted samples was analyzed by
SDS/PAGE or western blotting.
For western blotting, samples were run on a nonreducing
12% SDS gel, and the proteins were transferred to nitrocel-
lulose membranes. The membranes were blocked for 1 h at
room temperature in 10 mM Tris/HCl, 150 mM NaCl, and
0.05% Tween-20 (pH 7.5) (NaCl/Pi/Tween) supplemented
with 5% nonfat dry milk. The blots were probed with
primary antibody (0.2 lgmL1) in NaCl/Pi/Tween for 2 h
at room temperature, and washed three times with NaCl/
Pi/Tween. The blots were incubated for 1 h at room
temperature with the secondary antibodies diluted 30 000-
fold in NaCl/Pi/Tween, and then washed again three times
in NaCl/Pi/Tween. Proteins were visualized by submerging
the blots in 100 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2,
0.5 mM Nitro Blue tetrazolium, and 0.5 mM 5-bromo-4-
chloroindol-2-yl phosphate (pH 9.5).
Production of recombinant myostatin prodomain
in E. coli
Myostatin prodomain was expressed in E. coli BL21(DE3)
cells transfected with the pPR-IBA2A/myostatin prodomain
expression vector, essentially as described previously [22],
but with a modified protocol to refold the recombinant
protein.
Inclusion bodies isolated from 3 L of expression culture
were dissolved in 30 mL of 6 M guanidine-HCl, 100 mM
Tris/HCl, 10 mM EDTA, and 0.2% 2-mercaptoethanol
(pH 8.0), and stirred for 20 min. The solution was centri-
fuged at 16 000 g for 10 min, and the supernatant was rap-
idly diluted in 300 mL of 100 mM Tris/HCl, 2.5 mM
b-cyclodextrin, and 100 lM phenylmethanesulfonyl fluoride
(pH 7.5), and refolded for 24–48 h at 4 °C.
Protein precipitates were removed by centrifugation at
3500 g for 15 min and the protein solution was dialyzed
against 3 9 3 L of 100 mM Tris/HCl, 100 lM phen-
ylmethanesulfonyl fluoride and 0.005% 2-mercaptoethanol
(pH 8.0) at 4 °C for 36 h. Precipitates were removed by
centrifugation at 3500 g for 15 min and the protein solu-
tion was then concentrated on an Amicon stirred ultrafil-
tration cell (EMD Millipore, Billerica, MA USA) and
applied to a 20-mL Strep-Tactin Sepharose column. The
column was washed with 10 column volumes of 100 mM
Tris/HCl, 150 mM NaCl, 1 mM EDTA, 100 lM phen-
ylmethanesulfonyl fluoride, and 0.005% 2-mercaptoethanol
(pH 8.0), and the bound protein was eluted with the same
buffer containing 2.5 mM D-desthiobiotine. The eluted pro-
tein was dialyzed against 100 mM ammonium bicarbonate
(pH 8.0), lyophilized, further purified by chromatography
on a Sephacryl S-300 column equilibrated with 100 mM
ammonium bicarbonate (pH 8.0), and lyophilized.
The sequence of recombinant myostatin prodomain
consists of residues Asn24–Arg266 of prepromyostatin, an
N-terminal 20-residue extension including the Strep-tag
(MAWSHPQFEKGARRDRGPEF), and nine residues
(VDLQGDHGL) at the C-terminal end derived from the
expression plasmid. The calculated molecular mass of the
recombinant protein is 31 027 Da.
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Production of the N-terminal region of myostatin
prodomain (PRO43–115)
The cDNA coding for the Thr43–Thr115 region of human
prepromyostatin was amplified with the 5′-GAGAAT
TCCATATGACTTGGAGACAAAACACT-3′ sense and
5′-GAGTCGACGGATCCCTACGTTGTAGCGTGATA-3′
antisense primers from the pPR-IBA2A/myostatin prodo-
main expression plasmid used as the template. The amplim-
er was digested with NdeI and BamHI restriction enzymes,
and cloned into the pET-15b expression vector (EMD
Millipore) cut with the same restriction endonucleases.
After sequence verification of the pET-15b_PRO43–115
expression plasmid, E. coli BL21(DE3) cells were trans-
formed with the construct, and protein production and
inclusion body isolation were performed with the procedure
described previously [22].
Inclusion bodies were dissolved in 8 M urea, 100 mM
Tris/HCl, 10 mM EDTA, and 100 mM dithioerythritol
(pH 8.0), and gel-filtered on a Sephacryl S-300 column
equilibrated with the same buffer. Fractions containing the
recombinant protein were pooled and diluted
20-fold in 50 mM Tris/HCl and 5 mM EDTA (pH 8.0), with
constant stirring at 4 °C, and the solution was incubated
overnight at 4 °C. MgCl2 (7.5 mM) was added to the
refolding buffer, and the solution was applied to an Ni2+–
Sepharose resin. Unbound proteins were removed by wash-
ing with 10 column volumes of 20 mM Tris/HCl, 500 mM
NaCl, and 5 mM imidazole (pH 7.9) and three column vol-
umes of 20 mM Tris/HCl, 500 mM NaCl, and 30 mM imid-
azole (pH 7.9). The protein was eluted with 20 mM Tris/
HCl and 300 mM imidazole (pH 7.9) and lyophilized. The
lyophilized powder was dissolved in 50 mM ammonium
bicarbonate buffer (pH 8.0), and desalted on a Sepha-
dex G-25 column. The recombinant protein was further
purified by gel filtration on a Sephadex G-75 column equil-
ibrated with 50 mM ammonium bicarbonate buffer
(pH 8.0). Fractions were analyzed by SDS/PAGE, and
fractions containing pure monomeric PRO43–115 were
pooled and lyophilized.
The recombinant protein consists of the Thr43–Thr115
region of human prepromyostatin and an N-terminal exten-
sion of 21 residues that originates from the expression
plasmid and includes the His6-tag (MGSSHHHHHHSSG
LVPRGSHM). The calculated molecular mass of the
recombinant protein is 10 702 Da.
Production of the C-terminal region of myostatin
prodomain (PRO116–266)
The cDNA coding for the Glu116–Arg266 region of human
prepromyostatin was amplified with the 5′-GAGAATTCC
ATATGGAAACAATCATTACC-3′ sense and 5′-GAGT
CGACGGATCCCTACCTTCTGGATCTTTT-3′ antisense
primers from the pPR-IBA2A/myostatin prodomain plasmid
used as the template The amplimers were cloned into the
NdeI–BamHI restriction sites of the pET-15b plasmid, and
protein production and isolation of inclusion bodies were
performed with the same procedure as described above.
Ten milligrams of isolated inclusion bodies was suspended
in 100 mL of 6 M guanidine-HCl, 100 mM Tris/HCl, 10 mM
EDTA, and 0.2% 2-mercaptoethanol (pH 8.0), and stirred
for 2 h. The protein solution was dialyzed against 50 mM
ammonium bicarbonate buffer (pH 8.0), and the precipi-
tated protein was removed by centrifugation at 6500 g. The
supernatant was lyophilized, dissolved in 50 mM ammo-
nium bicarbonate buffer (pH 8.0), and gel-filtered on a
Sephacryl S-300 column equilibrated with 50 mM ammo-
nium bicarbonate (pH 8.0). Fractions containing pure
monomeric PRO116–266 were pooled and lyophilized.
The recombinant protein contains the Glu116–Arg266
region of human prepromyostatin and the same N-terminal
His-tag extension as PRO43–115 (MGSSHHHHHHSSGLV
PRGSHM). The calculated molecular mass of the recombi-
nant protein is 19 493 Da.
Production of recombinant human promyostatin
The DNA encoding human promyostatin was amplified
from human genomic DNA. The gene for human myosta-
tin precursor (residues 1–375) consists of three exons; the
three DNA segments encoding promyostatin (Asn24–
Ser375) were amplified and fused with the following prim-
ers: Exon1/sense, 5′-GACCGCGGTCAATGAGAACAGT
GAG-3′; Exon1/antisense, 5′-CTTGCATTAGAAAATCA
GACTCTGTAGGCATGGTAA-3′; Exon2/sense, 5′-TTA
CCATGCCTACAGAGTCTGATTTTCTAATGCAAG-3′;
Exon2/antisense, 5′-GACCTGTAAAAACGGATTCAGC
CCATCTTCTCGTGG-3′; Exon3/sense, 5′-CCAGGAGAA
GATGGGCTGAATCCGTTTTTAGAGGTC-3′; and Exon3/
antisense, 5′-CGCCATGGTTATGAGCACCCACAGCG
GTC-3′. Amplimers were linked in a two-step PCR reac-
tion: the first and second exons were linked in a PCR reac-
tion with primer Exon1/sense and primer Exon2/antisense,
and then, in a second reaction, the third exon was linked to
this amplimer with primer Exon1/sense and primer Exon3/
antisense. The DNA was digested with SacII and NcoI
restriction endonucleases, and ligated into the pPR-IBA2
bacterial expression vector (IBA BioTAGnology, Gottin-
gen, Germany) digested with the same restriction endonuc-
leases.
E. coli JM109 cells were transfected with the ligation
mixture, and clones containing the DNA of promyostatin
were identified. The sequences of promyostatin cDNA
inserts were determined, and plasmids containing correct
promyostatin cDNA inserts were used to transform
E. coli BL21(DE3) cells.
For protein production, bacteria were grown in 2TY
medium (1.6% tryptone, 1% yeast extract, 0.5% NaCl,
pH 7.5) containing 100 lgmL1 ampicillin; expression of
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recombinant protein was induced with 100 lM isopropyl
thio-b-D-galactoside. Cells containing the recombinant pro-
tein were digested with lysozyme, and sonicated three
times for 5 min in the presence of 1% Triton X-100.
Inclusion bodies were collected by centrifugation at 6500 g
for 10 min, washed three times with 10 mM Tris/HCl,
1 mM EDTA, and 0.1% Triton X-100 (pH 7.5), and dis-
solved in 30 mL of 6 M guanidine-HCl, 100 mM Tris/HCl,
5 mM EDTA, and 0.2% 2-mercaptoethanol buffer
(pH 8.0), by stirring for 2 h. The protein solution was
diluted 12-fold in the refolding buffer containing 100 mM
Tris/HCl, 0.5 M arginine-HCl, 1 M NaCl, 5 mM EDTA,
2.5 mM b-cyclodextrin, 2 mM oxidized glutathione, 10 mM
reduced glutathione, and 100 lM phenylmethanesulfonyl
fluoride (pH 8.5), with constant stirring at 4 °C.
The protein was allowed to refold for 3 days at 4 °C.
The solution was dialyzed against 100 mM Tris/HCl,
150 mM NaCl, and 100 lM phenylmethanesulfonyl fluoride
(pH 8.0), and was loaded onto a Strep-Tactin Sepharose
column (IBA BioTAGnology). Unbound protein was
removed with 10 column volumes of 100 mM Tris/HCl,
150 mM NaCl, and 100 lM phenylmethanesulfonyl fluoride
(pH 8.0); the bound protein was eluted with the same buf-
fer containing 2.5 mM desthiobiotin. The eluate was con-
centrated with an Amicon Ultra device (EMD Millipore),
and chromatographed on a Superdex-200 FPLC column
(GE Healthcare) in 100 mM Tris/HCl, 150 mM NaCl, and
100 lM phenylmethanesulfonyl fluoride (pH 8.0). Fractions
were analyzed by SDS/PAGE, and those containing pure
dimeric promyostatin were pooled (Fig. S1).
The sequence of recombinant promyostatin expressed in
E. coli consists of Asn24–Ser375 of prepromyostatin, and
an N-terminal Strep-tag (MASWSHPQFEKGAETAV)
derived from the expression vector. The calculated molecu-
lar mass of this recombinant protein is 41 955 Da.
Characterization of recombinant promyostatin
Myostatin/GDF8 is produced from a secreted extracellular
dimeric precursor protein (promyostatin) by proteolytic
processing (Fig. 1). After cleavage of a single peptide bond
by a furin-type protease, the N-terminal propeptides (myo-
statin prodomain) and the disulfide-bonded homodimer of
C-terminal mature growth factor domains remain associ-
ated, forming a complex known as the latent myostatin
complex. Active mature growth factor myostatin/GDF8
may be liberated from the latent complexes through degra-
dation of the prodomain; BMP-1 is known to play a key
role in the cleavage of the propeptide of latent myostatin
complex.
Our analyses of human promyostatin expressed in E. coli
and refolded with the protocol described above have
revealed that the protein has all the characteristics expected
of the native myostatin precursor.
First, under reducing conditions, the recombinant pro-
tein migrates as a monomer (~ 42 kDa), whereas under
nonreducing conditions it has a molecular mass of
~ 85 kDa, as expected for promyostatin, which is a dimer
covalently linked through a disulfide bond (Fig. S1).
Second, we have shown that recombinant promyostatin
is properly processed by furin. Incubation of promyostatin
(3000 nM) with recombinant human furin (3.5 lgmL1) in
100 mM Tris/HCl, 150 mM NaCl, 1 mM CaCl2 and 100 mM
phenylmethanesulfonyl fluoride (pH 8.0) at 28 °C resulted
in the formation of the myostatin prodomain and mature
myostatin, through an intermediate – semipromyosta-
tin – in which only one of the chains of promyostatin
dimer is cleaved (Fig. S2).
Third, we have shown that the prodomain of latent myo-
statin (produced by furin cleavage of recombinant prom-
yostatin) is properly cleaved by BMP-1. Furin-treated
myostatin preparations were dialyzed against 25 mM Hepes,
5 mM CaCl2, and 1 lM ZnCl2 (pH 7.5), and were incubated
with BMP-1 (5 lgmL1 final concentration) for 24 h at
37 °C. As shown in Fig. S3, latent myostatin is efficiently
processed by BMP-1; the prodomain is cleaved into an
~ 10-kDa fragment (PRO24–98) and an ~ 20-kDa fragment
(PRO99–266) (Fig. 1).
Fourth, latent myostatin yielded active myostatin follow-
ing the disruption of the prodomain–myostatin interaction
by BMP-1 cleavage or by incubation at 80 °C for 5 min
[27]. As expected, in a Smad2/Smad3-responsive luciferase
reporter system, promyostatin did not activate luciferase
transcription, whereas both heat-treated latent complex and
BMP-1-digested latent complex induced high levels of lucif-
erase expression, indicating that biologically active mature
myostatin may be released from the recombinant protein
(Fig. 2). Interestingly, our data were similar to those pre-
sented by Wolfmann et al. [27], in that, in these assays, the
latent myostatin complex always showed significantly
(P < 0.05) higher myostatin activity than control samples
(Fig. 2).
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